Motif Bio plc (AIM: MTFB) (NASDAQ: MTFB) has received a Notice of Allowance from the US Patent and Trademark Office, the biopharmaceutical company revealed on Wednesday.
The two new patents relate to the use of iclaprim to treat patients with bacterial infections, including acute bacterial skin and skin structure infections, hospital-acquired bacterial pneumonia and Staphylococcus aureus lung infections in patients with cystic fibrosis.
These patents give Motif Bio additional exclusivity for iclaprim in the treatment of bacterial infections through to November 2037.
Iclaprim is a novel investigational antibiotic with a targeted Gram-positive spectrum of activity. According to Motif Bio, in contrast to commonly used broad-spectrum antibiotics, this 'precision medicine' approach is consistent with antibiotic stewardship principles which, among other things, seek to reduce the inappropriate use of broad-spectrum products to avoid the build-up of resistance and to lessen the impact on the microbiome of the patient.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera